RxDoctor Payments DataLook up a doctor →

Robert Busch, MD

Endocrinology, Diabetes & Metabolism · Albany, NYNPI 1457358715

Payments from drug & device makers

$9,059,124in general payments, 2019–2025

Across 7,852 payments — averaging $1153.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$2.2M
  • Eli Lilly$2M
  • Lilly USA, LLC$726K
  • Novo Nordisk$536K
  • Sanofi US Services Inc.$385K
  • Novartis$320K
  • plus $2.8M from 51 others
$21,439in research payments, 2019–2025

Across 55 payments — averaging $389.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$8K
  • Eli Lilly$6K
  • Sanofi-aventis U.S. LLC$2K
  • Corcept Therapeutics$2K
  • AbbVie$2K
  • Gilead$970
  • plus $25 from 1 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS3,959$2,229,193
Eli Lilly223$2,034,046
Lilly USA, LLC955$725,880
Novo Nordisk577$536,193
Sanofi US Services Inc.44$384,871
Novartis33$319,891
AstraZeneca(2 entities)163$308,242
Bayer194$277,933
Sanofi-aventis U.S. LLC179$233,505
Kowa Research Institute, Inc.37$198,040
Amgen(2 entities)192$196,706
AbbVie(2 entities)50$195,334
Senseonics, Incorporated43$188,912
Boehringer Ingelheim205$172,711
Amarin Pharma, Inc.117$147,598
Corcept Therapeutics104$147,073
Johnson & Johnson137$142,684
Esperion Therapeutics, Inc.121$91,306
Lexicon Pharmaceuticals, Inc.3$75,423
Janssen Research & Development, LLC1$62,676
Merck57$46,602
Madrigal Pharmaceuticals49$38,246
Radius Health, Inc.38$38,135
Abbott97$37,294
Astrazeneca UK Limited4$32,844
Gilead17$28,459
Takeda Pharmaceuticals U.S.A., Inc.28$28,009
Intra-sana Laboratories22$26,363
Pfizer30$25,485
Renalytix AI, Inc.11$22,043
Ascendis Pharma Endocrinology Inc13$18,116
Chiasma, Inc.3$10,230
Shire North American Group Inc5$10,222
BD9$6,752
Ascensia Diabetes Care US Inc.2$4,675
Regeneron Healthcare Solutions, Inc.11$3,621
Regeneron8$3,474
Mannkind Corporation28$2,489
Chiesi USA, Inc.3$2,345
IBSA Pharma Inc.5$1,540
Amryt Pharma Holdings Ltd2$1,400
GRT US Holding, Inc.4$681
Boehringer Ingelheim International GmbH6$624
Insulet Corporation31$590
Dexcom, Inc.8$157
Ipsen Biopharmaceuticals, Inc8$143
Janssen Scientific Affairs, LLC3$127
OPKO Pharmaceuticals, LLC3$55
Embecta Corp.2$35
Rhythm Pharmaceuticals, Inc.1$28
Xeris Pharmaceuticals, Inc.1$21
Kowa Pharmaceuticals America, Inc.1$20
RGH Enterprises LLC1$19
Bigfoot Biomedical Inc1$19
Lifescan, Inc.1$16
Amneal Pharmaceuticals LLC1$14
Recordati_rare_diseases_inc.1$13

How this compares

$9,059,124 in reported general payments places this provider in the 95th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024
$33,351
Medicare patients
285
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Albany

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →